Short Interest in NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Drops By 15.5%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 9,001 shares, a decline of 15.5% from the November 30th total of 10,658 shares. Based on an average daily volume of 3,722 shares, the days-to-cover ratio is presently 2.4 days. Based on an average daily volume of 3,722 shares, the days-to-cover ratio is presently 2.4 days.

NeuroSense Therapeutics Stock Down 18.0%

NASDAQ:NRSNW opened at $0.32 on Wednesday. The company has a 50-day moving average price of $0.36 and a 200-day moving average price of $0.49. NeuroSense Therapeutics has a 12 month low of $0.12 and a 12 month high of $1.06.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.